|
C4ORF3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.66087193682097E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.54240003786322E-11 |
| Normal-vs-Stage2 |
6.08330000040347E-07 |
| Normal-vs-Stage3 |
9.02719998752133E-09 |
| Normal-vs-Stage4 |
8.68027871803179E-12 |
| Stage1-vs-Stage2 |
4.585800E-01 |
| Stage1-vs-Stage3 |
6.822600E-01 |
| Stage1-vs-Stage4 |
4.732200E-02 |
| Stage2-vs-Stage3 |
4.018400E-01 |
| Stage2-vs-Stage4 |
4.055800E-01 |
| Stage3-vs-Stage4 |
3.285700E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.3807184242678E-12 |
| Normal-vs-AfricanAmerican |
2.584600E-04 |
| Normal-vs-Asian |
1.31660000002309E-06 |
| Caucasian-vs-AfricanAmerican |
3.488000E-01 |
| Caucasian-vs-Asian |
7.391400E-01 |
| AfricanAmerican-vs-Asian |
5.734600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.35651514862911E-13 |
| Normal-vs-Female |
2.79130052405208E-10 |
| Male-vs-Female |
3.057800E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.76869996426632E-09 |
| Normal-vs-Age(41-60Yrs) |
5.10479991611135E-10 |
| Normal-vs-Age(61-80Yrs) |
6.82229828186109E-11 |
| Normal-vs-Age(81-100Yrs) |
6.443500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.791200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.682800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.190000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.151800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.809800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.252200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.203000E-01 |
| Classical-VS-Follicular |
2.384900E-03 |
| Classical-VS-Other |
2.386100E-02 |
| Classical-VS-Normal |
2.90000023994708E-10 |
| Tall-VS-Follicular |
2.215800E-01 |
| Tall-VS-Other |
2.701400E-01 |
| Tall-VS-Normal |
4.12249999692804E-08 |
| Follicular-VS-Other |
4.983400E-01 |
| Follicular-VS-Normal |
6.48603393216263E-12 |
| Other-VS-Normal |
1.71419999999145E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.7719610181457E-12 |
| Normal-vs-N1 |
4.38579950134965E-10 |
| N0-vs-N1 |
7.090500E-02 |
|
|
